The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
More top news
Some 26% of online shoppers complained of poor delivery service.
A man thought to be the first person in the world to recover from complete severing of the spinal nerves is able to walk again after surgery
Salisbury has been named among the top 10 cities in the world to visit by travel guide Lonely Planet.